This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
What's in Store for Dow ETF in Q1 Earnings?
by Sweta Killa
Let's delve into the Q1 earnings picture that will likely set up the movement of the Dow Jones ETF in the coming days.
Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
by Zacks Equity Research
Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).
Alkermes Reports Positive Data From Schizophrenia Study
by Zacks Equity Research
Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
by Zacks Equity Research
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?
by Zacks Equity Research
J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.
5 Stocks to Prepare for a Global Economic Slowdown
by Swarup Gupta
In such an event, demand for products and services generated by utilities, consumer staples and medical companies remain invariant.
Johnson & Johnson (JNJ) Stock Moves -0.47%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $135.50 in the latest trading session, marking a -0.47% move from the prior day.
Earnings Preview: Johnson & Johnson (JNJ) Q1 Earnings Expected to Decline
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients
by Zacks Equity Research
Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
by Zacks Equity Research
Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
J&J Stock on an Uptrend This Year So Far: More Room to Run?
by Zacks Equity Research
J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.
Company News For Apr 8, 2019
by Zacks Equity Research
Companies In The News Are: BA, ABMD, TGI, C, JNJ
Editas (EDIT) Inks Cross Licensing Agreement with BlueRock
by Zacks Equity Research
Editas (EDIT) inks a research and cross licensing agreement with BlueRock Therapeutics, LP.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $137.17, moving -0.39% from the previous trading session.
Roche Extends Offer Period for Spark Therapeutics Acquisition
by Zacks Equity Research
Roche (RHHBY) withdraws its Premerger Notification and Report Form in connection with the pending acquisition of Spark Therapeutics.
Novartis Gets Approval for Psoriasis Drug Cosentyx in China
by Zacks Equity Research
Novartis' (NVS) psoriasis drug gets approval in China. The company also signs an agreement to expand its biologics therapy manufacturing capability.
Company News For Apr 2, 2019
by Zacks Equity Research
Companies in the news are: JNJ, SCOR, VFF and TGTX
Spero Gets Fast Track Designation for SPR994, Shares Improve
by Zacks Equity Research
Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.
AstraZeneca's Selumetinib Gets Breakthrough Therapy Status
by Zacks Equity Research
AstraZeneca's (AZN) MEK 1/2 inhibitor, selumetinib gets Breakthrough Therapy designation for the treatment of paediatric patients with inoperable NF1-related PN.
3 Big Pharma Stocks to Add to Your Portfolio This April
by Kinjel Shah
The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
AstraZeneca (AZN) Signs $6.9B Cancer Deal with Daiichi Sankyo
by Kinjel Shah
AstraZeneca (AZN) signs a collaboration deal, potentially costing $6.9 billion, with Japan's Daiichi Sankyo to develop/commercialize a promising cancer treatment.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals
by Zacks Equity Research
AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
Dow 30 Stock Roundup: Apple Launches New Services, JPMorgan to Trim Wealth Jobs
by Swarup Gupta
The index enjoyed quite a positive week even as a yield curve inversion weighed on broader markets.
Axsome's Depression Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Axsome (AXSM) announces that the FDA has granted Breakthrough Therapy designation to AXS-05 for the treatment of major depressive disorder (MDD).